Janux Therapeutics (JANX) News
NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.39-0.11 (-0.59%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
JANX news summary
We found 2 recent headlines mentioning Janux Therapeutics (JANX): 0 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, JANX is down 0.59% at $18.39. The most recent story, "The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux", was published by Nasdaq on Sep 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Janux Therapeutics headlines
- The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and JanuxProstate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.NasdaqNVS, PFE, JANX, CADL
- 4 Prostate Cancer Drug Stocks to Watch During Awareness MonthPfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.NasdaqNVS, PFE, JANX, CADL